As of 2026-09-16, the EV/EBITDA ratio of Castle Biosciences Inc (CSTL) is -60.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CSTL's latest enterprise value is 1,024.94 mil USD. CSTL's TTM EBITDA according to its financial statements is -16.96 mil USD. Dividing these 2 quantities gives us the above CSTL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.1x - 9.7x | 9.5x |
| Forward P/E multiples | 9.0x - 9.7x | 9.4x |
| Fair Price | (3.39) - (3.71) | (3.58) |
| Upside | -109.6% - -110.4% | -110.1% |
| Date | EV/EBITDA |
| 2026-09-14 | -56.74 |
| 2026-09-11 | -54.75 |
| 2026-09-10 | -54.73 |
| 2026-09-09 | -54.72 |
| 2026-09-08 | -55.52 |
| 2026-09-04 | -55.79 |
| 2026-09-03 | -55.32 |
| 2026-09-02 | -56.70 |
| 2026-09-01 | -56.74 |
| 2026-08-31 | -56.00 |
| 2026-08-28 | -56.84 |
| 2026-08-27 | -58.20 |
| 2026-08-26 | -57.88 |
| 2026-08-25 | -59.52 |
| 2026-08-24 | -56.79 |
| 2026-08-21 | -58.09 |
| 2026-08-20 | -55.82 |
| 2026-08-19 | -54.73 |
| 2026-08-18 | -48.85 |
| 2026-08-17 | -50.50 |
| 2026-08-14 | -49.91 |
| 2026-08-13 | -51.57 |
| 2026-08-12 | -53.14 |
| 2026-08-11 | -54.59 |
| 2026-08-10 | -54.79 |
| 2026-08-07 | -54.21 |
| 2026-08-06 | -51.43 |
| 2026-08-05 | -51.30 |
| 2026-08-04 | -52.69 |
| 2026-08-03 | -51.28 |
| 2026-07-31 | -47.01 |
| 2026-07-30 | -44.85 |
| 2026-07-29 | -40.68 |
| 2026-07-28 | -39.66 |
| 2026-07-27 | -40.64 |
| 2026-07-24 | -41.08 |
| 2026-07-23 | -42.50 |
| 2026-07-22 | -41.31 |
| 2026-07-21 | -40.77 |
| 2026-07-20 | -39.67 |
| 2026-07-17 | -40.14 |
| 2026-07-16 | -40.27 |
| 2026-07-15 | -39.89 |
| 2026-07-14 | -38.28 |
| 2026-07-13 | -38.03 |
| 2026-07-10 | -39.36 |
| 2026-07-09 | -40.86 |
| 2026-07-08 | -39.21 |
| 2026-07-07 | -39.55 |
| 2026-07-06 | -40.23 |